Bioshares provided another update on Opthea earlier this week...

Bioshares provided another update on Opthea earlier this week entitled "Major Inflexion points for Opthea in 2019 as case for positive results build". The article included a number of comments from Megan Baldwin which were made at a recent investor meeting. These included Baldwin's belief that the company's recent share price surge could be attributed to the anticipation of data release nearing closer with AMD trial results due in 4th quarter and DME results in 2H this year. In addition she believes the valuation of the business will far exceed the current price if the company hits its endpoints in its current studies.

While I did not intend to increase my holdings in Opthea any further I have now purchased another few thousand shares.